From Battlefield to Public Health Policy
In this Delphi Insight Session, Dr Leith States discusses psychedelic-assisted therapies and ibogaine and how they can impact public health.
delphiwp
Texas Ibogaine, Australia Veterans, and Freedom to Heal
This month, the strongest policy signal is that access is being built from multiple directions at once. Texas is using state dollars to stand up an ibogaine clinical trial consortium, federal lawmakers are trying to unlock a pre-approval access pathway for Schedule I psychedelics, and health systems abroad are moving from “permission” to “payment” with tighter delivery rules.
Operational Benchmarks for Psychedelic Care
December 2025’s studies add practical detail to a shift already underway: psychedelic care is moving from “can it work” to “how do we deliver it safely, consistently, and in a way payers can cover.”
Microdosing Shows Minimal Effects While Macrodose Studies Continue to Impress
November 2025 delivered a sharp reality check for psychedelic microdosing while macrodose studies advanced treatment options for depression, PTSD, and end-of-life distress.
Veterans, Microdosing, and Faster Psilocybin Timelines
Psychedelic Policy News from November 2025 where we cover veterans getting access, faster psilocybin approval, and micro(dosing) results.
Unlocking Safe Ibogaine Care
In this Delphi Insight Session, Lia Mix shares her journey with trauma and healing, and how Delphi and IHPI are advancing Ibogaine therapy.
Real-World Data Sharpen the Case for Safe and Effective Psychedelic Therapies
New psychedelic studies from October show 5-year safety data from esketamine, the importance of set & setting, and microdosing null-results.
New Psychedelic Studies Advance Clinical Applications
New psychedelic studies from September show psilocybin for addiction, LSD for anxiety, and group therapy for burnout, guiding clinical and policy integration.
Tracking Real World Psychedelic Use Nationwide
Kate Reynolds from Rocky Mountain Poison and Drug Safety (RPMDS) discusses how NSIHT tracks real world psychedelic use nationwide.
Psychedelics and Reimbursement in Europe
Join Lia Mix, CEO of Delphi, and Floris Wolswijk, Senior Policy and Research Partner at Delphi, for the third Delphi Insight Session on reimbursement pathways for psychedelic therapies in Europe.
